Evidence map›Paper›PMID 26108656›Full record

ReviewJournal of neuro-oncology2015

Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?

Shailendra Joshi, Jason A Ellis, Eugene Ornstein, Jeffrey N Bruce

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Bevacizumab: The future of chronic subdural hematoma.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. A Distinct Advantage to Intraarterial Delivery ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  17. Review
  18. Article
  19. Advances in drug delivery to high grade gliomas.Brain pathology (Zurich, Switzerland) · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shailendra JoshiDepartment of Anesthesiology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, P&S Box 46, New York, NY, 10032, USA. sj121@cumc.columbia.edu.
Jason A EllisDepartment of Neurological Surgery, Columbia University Medical Center, New York, NY, USA. jae2109@columbia.edu.
Eugene OrnsteinDepartment of Anesthesiology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, P&S Box 46, New York, NY, 10032, USA.
Jeffrey N BruceDepartment of Neurological Surgery, Columbia University Medical Center, New York, NY, USA.

Funding

Optical Imaging of Chemotherapy for Brain TumorsR01CA138643 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JOSHI, SHAILENDRA · 2011 to 2015
$2.4M
NCI NIH HHS R01 CA138643NCI NIH HHS R01-CA-138643
6 · The paper itself

Abstract

Intraarterial (IA) drug delivery is a physiologically appealing strategy as drugs are widely distributed throughout the tumor capillary network and high regional tissue concentrations can be achieved with low total doses. IA treatment of glioblastoma multiforme (GBM) has been attempted since the 1950s but success has been elusive. Although IA treatments have been embraced for the treatment of retinoblastoma and advanced liver cancers, this has not been the case for GBM. The development of IA drug delivery for the treatment of brain cancer over the last several decades reveals a number of critical oversights. For example, very few studies took into consideration the underlying hydrodynamic factors. Therapeutic failures were often blamed on an inability to penetrate the blood brain barrier or on the streaming of drugs. Similarly, there were few methods to investigate the ultra-fast pharmacokinetics of IA drugs. Despite past failures, clinical interest in IA drugs for the treatment of GBM persists. The advent of modern imaging methods along with a better understanding of hydrodynamics factors, better appreciation of the complex morphology of GBM, improved drug selection and formulations, and development of methods to minimize treatment-related neurological injury, promise to considerably advance the application of IA drugs for GBM treatment. There are several clinical trials with IA treatments in the National Trial Registry that are actively recruiting patients. This review of IA drug delivery for GBM treatment is therefore timely and is intended to assess how this method of drug delivery could be better applied to future treatments.

Indexed as

Drug Delivery SystemsAntineoplastic AgentsBrain NeoplasmsGlioblastomaHumansInfusions, Intra-ArterialAntineoplastic AgentsBlood–brain barrierBrain tumorChemotherapyGlioblastoma multiformeGliomaIntraarterial

Identifiers

PMID26108656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.